Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002388
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of 1592U89 in HIV-Infected Patients
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Study to Evaluate the Single-Dose and Steady-State PharmacokineticsDynamics of 1592U89 and Its Active Moiety 1144U88 5-Triphosphate 1144U88-TP Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects
Status:
COMPLETED
Status Verified Date:
1998-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients This study also examines the effect 1592U89 has on plasma viral load the level of HIV in the blood
Detailed Description:
Cohorts of 8 patients are entered sequentially into 1 of 6 1592U89 dosing regimens All patients receive 12 weeks of monotherapy during the initial 12-week treatment phase
On completion of the treatment phase patients are offered continuation therapy with 1592U89 for a minimum of 12 weeks
On completion of the treatment phase patients are offered continuation therapy with 1592U89 for a minimum of 12 weeks
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CNAA1004 | None | None | None |